The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.Metsera on Tuesday said Novo Nordisk's new bid for the obesity biotech is "superior" to a revised offer from Pfizer, escalating a heated tussle over the startup between the two pharmaceutical giants. Novo Nordisk's new proposal values Metsera at up to $86. ...

Bagsværd, Denmark, 4 November 2025 – On 30 October 2025, Novo Nordisk announced the submission of an unsolicited proposal to acquire Metsera, Inc. (Metsera)1. Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior by Metsera’s board of directors. The acquisition of Metsera, including its early and development-stage incretin and non-incretin analogue peptide programmes, would provide Novo Nordisk the opportunity ...

Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday. ...

智通财经APP获悉，辉瑞(PFE.US)公布了好于预期的2025年第三季度业绩，同时上调了全年盈利预期。该公司表示，持续推进的成本削减措施 帮助弥补了销售增长放缓带来的压力，这也为其竞购减肥药初创公司Metsera(MTSR.US)提供了资金支持。 财报显示，辉瑞Q3营收同比下降6%至166.54亿美元，好于分析师普遍预期的165亿美元;调整后的净利润为49.49亿美元，同比下降18%;调整后的 每股收益为0.87美元，好于分析师普遍预期的0.64美元。 | ($ in millions, except per share | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | amounts) | Third-Quarter | | | | Nine Months | | | | 2025 | 2024 | % Change | 2025 | 2024 | % Change | | Revenues | $ 16,654 | $ 17,702 | (6%) | $ 45,022 | $ 45,864 | (2%) | | Reported(3) ...

Core Viewpoint - Nova Nordisk has faced significant challenges in 2025, with its stock down approximately 50% year-to-date due to increased competition and a weak product pipeline [1][2]. Company Performance - The company has struggled with the rise of copycat drugs and a lack of new product innovations, leading to lowered performance expectations [2]. - In July, Nova Nordisk informed investors that its full-year performance would be below initial expectations [3]. - The company announced a transformation strategy in September, which includes cutting 9,000 jobs and aiming for annualized cost savings of about 8 billion Danish crowns [3]. Leadership Changes - The pressure on the stock led to the ousting of CEO Lars Jorgensson in May, who had been in the role since 2017 [2]. - Mike Dowster, the new CEO, is tasked with revitalizing the company and implementing the transformation strategy [3]. Market Sentiment - Analysts have shown a more positive outlook following the new strategy announcement, with five stock analysts raising their outlook on the stock [4]. - Rothschild and Co analysts noted that the previous valuation of Nova Nordisk could not be justified on fundamental grounds, but this perspective has changed [4]. Future Outlook - Investors will closely monitor Nova Nordisk's upcoming financial results to assess the effectiveness of the transformation strategy and potential for innovation and deal-making [5].

2025.11. 04 本文字数：1535，阅读时长大约2分钟 作者 | 第一财经 钱童心 当地时间11月3日，美国制药公司辉瑞对丹麦制药公司诺和诺德提起第二起诉讼，指控诺和诺德试图以高于辉瑞的出价收购减重药厂商Metsera公司构成 反竞争行为。 辉瑞在当天提交给美国特拉华州地方法院的诉讼文件中还指控Metsera公司的控股股东与诺和诺德串通，试图影响新药的研发进程。 上周五，辉瑞已经请求特拉华州法院发布临时禁制令，以阻止Metsera终止与辉瑞之间的协议。 辉瑞声称，诺和诺德的出价并非真正为了收购Metsera的药物研发管线，而是一种战略策略，目的是维护目前司美格鲁肽的市场份额。 辉瑞还诉讼指控诺和诺德在监管审查之前就向Metsera股东提供65亿美元的预付款，并提出限制性条款，从而延迟或阻止新药的临床进展。 对此，诺和诺德负责媒体关系的全球副总裁Ambre James Brown在一份声明中表示："辉瑞公司声称诺和诺德打算通过收购要约来压制创新，这种说法 毫无根据，纯属捏造。" 她进一步指出，辉瑞没有在价格上进行竞争，而是采取了"极其不寻常且看似孤注一掷的方式"，提起了反垄断诉讼。诺和诺德的收购要约，包 ...

诺和诺德在减重药市场的主导地位正在受到挑战。 当地时间11月3日，美国制药公司辉瑞对丹麦制药公司诺和诺德提起第二起诉讼，指控诺和诺德试图以高于辉瑞的出价收购减重药厂商Metsera公司构成反竞 争行为。 辉瑞在当天提交给美国特拉华州地方法院的诉讼文件中还指控Metsera公司的控股股东与诺和诺德串通，试图影响新药的研发进程。 上周五，辉瑞已经请求特拉华州法院发布临时禁制令，以阻止Metsera终止与辉瑞之间的协议。 她进一步指出，辉瑞没有在价格上进行竞争，而是采取了"极其不寻常且看似孤注一掷的方式"，提起了反垄断诉讼。诺和诺德的收购要约，包括交易结构， 都符合所有适用法律，并且符合患者和Metsera公司股东的最大利益。 Metsera公司也表示，最新的诉讼是辉瑞试图压低收购价格的手段。该公司在一份声明中称辉瑞的指控"毫无根据"，并表示将在法庭上回应这些指控。 最新的诉讼加剧了辉瑞与诺和诺德之间围绕Metsera公司的激烈对峙，Metsera在研的减重药管线有望催生年收入50亿美元的新市场。 自今年年初以来，该公司已经收到7份收购要约，诺和诺德的最终报价令该公司的整体估值达到90亿美元，高出辉瑞报价超10亿美 ...

By Sabrina Valle, Mrinalika Roy and Tom Hals (Reuters) -Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for Metsera to stall the entry of the biotech firm's treatments into the obesity drug market rather than being aimed at closing a deal. Novo and Metsera on Monday rejected Pfizer's claims, which were a dramatic escalation in the fight for control of the biotech startup. A judge will analyze the complaints on Tuesday. Pfizer agreed to pay ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S. rival Pfizer. ...

| | | 全球主要股票指数 | | | | --- | --- | --- | --- | --- | | 市场 | 名称 | 现价 | 涨跌 | 涨跌幅 | | 欧美 | 道琼斯工业平均 | 47336.68 | -226.19 | -0.48% | | | 纳斯达克 | 23834.72 | 109.76 | 0.46% | | | 标普500 | 6851.97 | 11.77 | 0.17% | | | 欧洲斯托克50 | 5679.25 | 17.21 | 0.30% | | | 英国富时100 | 9701.37 | -15.88 | -0.16% | | | 法国CAC40 | 8109.79 | -11.28 | -0.14% | | | (西日DAY -- 100 | | 24132.41.80 gud at 94.99m | 0.73% | | | 俄罗斯RTS | 1001.3 | 18.91 | 1.92% | | | 上证指数 | 3976.52 | 21.73 | 0.55% | | | 深证成指 | 13404.06 | 25.85 | 0.19% | | | 创业板指 | 3 ...